Companies › Daewon Pharmaceutical
3 active drug programs in 3 registered trials: 2 Phase 3, 1 Phase 1; Immunology, Other.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| DW1807 | – | Phase 3 | Perennial Allergic Rhinitis Accompanied by Asthma | – |
| DW1807-R2 | – | Phase 3 | Perennial Allergic Rhinitis Accompanied by Asthma | – |
| DW4421 | – | Phase 1 | Healthy Adult | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07343245 | DW4421 | Phase 1 | Healthy Adult | Other | Feb 2026 |
| NCT07168473 | DW1807 | Phase 3 | Perennial Allergic Rhinitis Accompanied by Asthma | Immunology | Aug 2026 |
| NCT07168473 | DW1807-R2 | Phase 3 | Perennial Allergic Rhinitis Accompanied by Asthma | Immunology | Aug 2026 |
No annotated target.
–
Astria Therapeutics Accro Bioscience (Suzhou) Prime Gene Therapeutics Zhejiang Sunshine Mandi Pharmaceutical Paradigm Biopharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.